Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

692584

registered interest
date	21/02/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 20 February 2017 to Question 63820, if he will take steps to increase the maximum length of time for which data can be collected on treatments funded from the Cancer Drugs Fund from two to three years.
tabling member constituency	Mid Derbyshire
tabling member printed	Pauline Latham
uin	64926
answer	answer is ministerial correction date of answer 01/03/2017 answer text <p>There is no maximum length of time for which data can be collected on treatments funded from the Cancer Drugs Fund (CDF). The duration in the CDF for a cancer drug is determined on an individual basis by the time required for such data development/collection to take place. This will depend on the disease concerned, the data that needs to be examined, the clinical trials that may be already running, and considerations of cancer treatment pathways in England. The time that a drug stays in the CDF is therefore individually assessed and agreed with NHS England, the National Institute for Health and Care Excellence and the company concerned. The timeframe will normally be up to two years, but will be considered on a case by case basis.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 01/03/2017 13:42:43 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4025 label Biography information for Mrs Pauline Latham

688010

registered interest
date	09/02/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to increase the length of time that data is collected on the evaluation of treatment funded by the Cancer Drugs Fund.
tabling member constituency	Mid Derbyshire
tabling member printed	Pauline Latham
uin	63820
answer	answer is ministerial correction date of answer 20/02/2017 answer text <p>NHS England has advised that cancer drugs that are assessed by the National Institute for Health and Care Excellence (NICE) as having both key clinical uncertainties and plausible cost effectiveness can enter the Cancer Drugs Fund (CDF) for evaluation with a view to future NICE re-appraisal once there is sufficient data from continuing clinical trials and/or data collection in the CDF.</p><p> </p><p>The duration in the CDF for a cancer drug is determined on an individual basis by the time required for such data development/collection to take place. This will depend on the disease concerned, the data that needs to be examined, the clinical trials that may be already running, and considerations of cancer treatment pathways in England. The time that a drug stays in the CDF is therefore individually assessed and agreed with NHS England, NICE and the company concerned.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 20/02/2017 12:02:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4025 label Biography information for Mrs Pauline Latham

657133

registered interest
date	12/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Skin Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps are being taken to ensure melanoma patients have access to the most clinically effective treatment options if they have (a) brain metastases and (b) previously taken part in a clinical trial.
tabling member constituency	Mid Derbyshire
tabling member printed	Pauline Latham
uin	57206
answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>The National Institute for Health and Care Excellence (NICE) has recommended a number of drugs for use in the treatment of melanoma. National Health Service patients have a right in the NHS Constitution to drugs and treatments that have been recommended by NICE, where clinically appropriate.</p><p> </p><p>NHS England has advised that it has carefully translated the evidence base on which NICE has based its recommendations of clinical and cost effectiveness for drugs and treatments for melanoma into practical clarifications which directly relate to how the recommended drug indication is incorporated into known treatment pathways in use in England.</p><p> </p><p>Each set of clarifications is in keeping with the NICE recommendations within the marketing authorisation of the relevant drug.</p><p> </p><p>The treatment criteria for both Cancer Drugs Fund and baseline-funded drug indications are set out in the National Cancer Drugs Fund List which is available at:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf</a></p><p> </p><p>Discussions are taking place with NHS regional and National Cancer Research Institute experts on melanoma on formulating chemotherapy algorithms for the treatment of advanced or metastatic melanoma. These discussions relate in part to the drug treatment of brain metastases and the need to preserve recruitment to clinical trials and whether the qualifications that NHS England has applied in terms of treatment criteria for melanoma drugs within their respective marketing authorisations should be changed.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 20/12/2016 10:30:04 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4025 label Biography information for Mrs Pauline Latham